×
About 375 results

ALLMedicine™ Alopecia Universalis Center

Research & Reviews  108 results

Unique Treatment for Alopecia Areata Combining Epinephrine With an Intralesional Steroid
https://www.mdedge.com/dermatology/article/256923/hair-nails/unique-treatment-alopecia-areata-combining-epinephrine
Eugeniu Stratulat, MD, Terri Shih, BS et. al.

Aug 9th, 2022 - Alopecia areata (AA) is an autoimmune disorder characterized by transient hair loss with preservation of the hair follicle (HF). The lifetime incidence risk of AA is approximately 2%,1 with a mean age of onset of 25 to 36 years and with no clinica.

JAAD Game Changers: Topical 2% tofacitinib for children with alopecia areata, alopecia ...
https://doi.org/10.1016/j.jaad.2022.07.033
Journal of the American Academy of Dermatology; Cotton CH

Aug 7th, 2022 - JAAD Game Changers: Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis.|2022|Cotton CH,|

Alopecia Areata
http://emedicine.medscape.com/article/1069931-overview

Jun 13th, 2022 - Practice Essentials Alopecia areata is a recurrent nonscarring type of hair loss that can affect any hair-bearing area and can manifest in many different patterns. Although it is a benign condition and most patients are asymptomatic, it can cause ...

Alopecia Areata
https://emedicine.medscape.com/article/1069931-overview

Jun 13th, 2022 - Practice Essentials Alopecia areata is a recurrent nonscarring type of hair loss that can affect any hair-bearing area and can manifest in many different patterns. Although it is a benign condition and most patients are asymptomatic, it can cause ...

Alopecia Areata Clinical Presentation
http://emedicine.medscape.com/article/1069931-clinical

Jun 13th, 2022 - History The natural history of alopecia areata is unpredictable. Extreme variations in duration and extent of the disease occur from patient to patient. Alopecia areata most often is asymptomatic, but some patients (14%) experience a burning sensa...

see more →

Clinicaltrials.gov  12 results

Clinical Trial to Evaluate the Efficacy of Fecal Microbiota Transplantation in Patients With Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT04238091

Mar 21st, 2022 - Alopecia areata (AA) is an autoimmune condition resulting in chronic and relapsing hair loss. AA patchy is associated with well-circumscribed patches of hair loss, commonly on the scalp or face, while alopecia totalis (AT) and alopecia universalis...

Clinical Application of Stem Cell Educator Therapy in Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT04011748

Jun 30th, 2021 - Alopecia areata (AA) is a common autoimmune disease that results in loss of body hair in varying degrees. The condition is estimated to affect more than 6.5 million people in the United States alone (naaf.org), with a worldwide prevalence of 0.1% ...

Fecal Transplant for Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT04833179

Apr 6th, 2021 - Alopecia areata (AA) is a common autoimmune disease that triggers non scarring hair loss in different severities. Usually the hair loss will be contained to the scalp and / or beard, but in some cases, there will be total hair loss from the entire...

A Study of Secukinumab for the Treatment of Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT02599129

Mar 11th, 2021 - Alopecia areata is a medical condition, in which the hair falls out in patches. The hair can fall out on the scalp or elsewhere on the face and body. Alopecia areata is an autoimmune skin disease, which means that the immune system is recognizing ...

ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)
https://clinicaltrials.gov/ct2/show/NCT03759340

Oct 6th, 2020 - This Phase 2, multicenter, open-label study will evaluate the safety, tolerability, efficacy, and durability of efficacy of ATI-502 Topical Solution, 0.46% for the treatment of alopecia areata (AA), alopecia universalis (AU) and alopecia totalis (...

see more →

News  30 results

Unique Treatment for Alopecia Areata Combining Epinephrine With an Intralesional Steroid
https://www.mdedge.com/dermatology/article/256923/hair-nails/unique-treatment-alopecia-areata-combining-epinephrine
Eugeniu Stratulat, MD, Terri Shih, BS et. al.

Aug 9th, 2022 - Alopecia areata (AA) is an autoimmune disorder characterized by transient hair loss with preservation of the hair follicle (HF). The lifetime incidence risk of AA is approximately 2%,1 with a mean age of onset of 25 to 36 years and with no clinica.

Focal hair loss
https://www.mdedge.com/familymedicine/article/254363/dermatology/focal-hair-loss
MDedge Family Medicine;

May 5th, 2022 - The findings of smooth, round alopecia occurring rapidly without associated scarring, pain, or itching, is consistent with the diagnosis of alopecia areata. Alopecia areata is a common autoimmune disease caused by T lymphocytes targeting hair foll.

JAK Inhibitor Provides Impressive Hair Growth for Patients With Alopecia Areata
https://www.medscape.com/viewarticle/960162

Oct 4th, 2021 - Baricitinib, an oral inhibitor of Janus kinase (JAK) types 1 and 2, produced substantial rates of hair growth with acceptable tolerability for patients with alopecia areata, according to the results of two phase 3 trials presented at the European ...

Microbiome: Gut dysbiosis linked to development of alopecia areata
https://www.mdedge.com/dermatology/article/244445/hair-nails/microbiome-gut-dysbiosis-linked-development-alopecia-areata
Jeff Craven

Aug 19th, 2021 - Patients with alopecia areata (AA) appear to have a gut dysbiosis not seen in healthy individuals, according to research presented at the annual meeting of the Society for Investigative Dermatology. There have been reports of gut microbiome dysbio.

Remote-Onset Alopecia Areata Attributed to Ipilimumab
https://www.mdedge.com/dermatology/article/215086/hair-nails/remote-onset-alopecia-areata-attributed-ipilimumab
David R. Pearson, MD, Karl Lewis, MD et. al.

Jan 7th, 2020 - Cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) is a key co-stimulatory receptor expressed on activated T cells that negatively regulates T-cell activation. 1-3 It exerts its effects in part by the prevention of IL-2 transcription and inhibiti.

see more →